Loading...

Gdpawel's Recent CancerCompass Activity

  • Gdpawel has created a new message board discussion

    In targeted gene therapy - the targeted gene or "driver" oncogene - doctors use a therapy that works on just one gene, then it's possible for tumors to shrink. Unfortunately, those tumors will eventually find a way to subvert that gene. There is some twelve main gene signaling pathways in cancer. Gene signaling is part of a complex system of communication that governs cellular activity and coordinates cell action. I...

    March 03 at 8:46 PM view discussion
    • Gdpawel has replied to a post on the message board

      I’ve been researching cell function analysis for the last 12 years, and even during that period, I’ve come across the resistance mechanism from the so-called trialist system, time and time again. I’ve researched the history of this apprehension; one example coming from NCI’s feeble attempt to study assay-directed therapy of lung cancer some years ago.The study was a failure because it was done...

      March 03 at 8:41 PM view post
      • Gdpawel has replied to a post on the message board

        Would it be safe to say that one of the reasons medical oncologists don’t like in vitro chemosensitivity tests is that it may be in direct competition with the randomized controlled clinical trial paradigm – a fiercely defended relic of our ignorance? Cell culture assays measure the “efficacy” of anti-cancer drugs. The randomized clinical trial measures the “efficacy” of anti-cance...

        March 03 at 8:40 PM view post
        • Gdpawel has replied to a post on the message board

          Robert Nagourney, M.D.In human experience, the level of disappointment is directly proportional to the level of expectation. When, for example, the world was apprised of the successful development of cold fusion, a breakthrough of historic proportions, the expectations could not have been greater. Cold fusion, the capacity to harness the sun’s power without the heat and radiation, was so appealing that people r...

          March 03 at 8:39 PM view post
          • Gdpawel has replied to a post on the message board

            Replies to comments regarding personalized cancer treatment, as published in the December 15, 2013 "ASCO Post" (American Society of Clinical Oncology publication).By Larry Weisenthal, MDDecember 15, 2013, Volume 4, Issue 20Dr. Mason states that I implied that Dr. Telli supports the routine application of chemosensitivity assays. I have no knowledge regarding Dr. Telli’s views on this subject, nor did I in any w...

            February 20 at 6:47 AM view post
            • Gdpawel has replied to a post on the message board

              To my knowledge, there hasn't been a clinical trial of any predictive test to show clinical benefit in a prospective randomized trial, in which patients are randomized to treatment on the basis of test results versus treatment without benefit of test results (the only exception to this is the British LRF-4 study, which showed improved one year survival for CLL patients treated on the basis of test results, compared t...

              February 20 at 6:40 AM view post
              • Gdpawel has created a new message board discussion

                Huntington Beach, CA - SignatureCLL announced that the first laboratory test ever shown in a clinical trial to improve one year survival rates in cancer is now available to patients with chronic lymphocytic leukemia (also called CLL).The U.S. cancer physician who invented the test and the British scientist who used it to make discoveries in leukemia will offer the test under the trade name SignatuRx through their own...

                February 20 at 6:35 AM view discussion
                • Gdpawel has replied to a post on the message board

                  Replies to comments regarding personalized cancer treatment, as published in the December 15, 2013 "ASCO Post" (American Society of Clinical Oncology publication).By Larry Weisenthal, MDDecember 15, 2013, Volume 4, Issue 20Dr. Mason states that I implied that Dr. Telli supports the routine application of chemosensitivity assays. I have no knowledge regarding Dr. Telli’s views on this subject, nor did I in any w...

                  December 17 at 5:11 AM view post
                  • Gdpawel has replied to a post on the message board

                    What research scientists in universities and cancer centers have been doing for the past ten years is trying to figure out a way to use this molecular profiling to look for patterns of gene expression which correlate with and predict for the activity of anticancer drugs (drug selection). However, genes do not operate alone within the cell but in an intricate network of interactions. Examing a patient's DNA can give ...

                    November 26 at 4:58 PM view post
                    • Gdpawel has replied to a post on the message board

                      The LRF CLL4 trial is the first-ever prospective, randomized clinical cytometric profiling trial that involves the DISC assay. The study is focused entirely in CLL. It certainly does prove the principle of cytometric profiling in exactly the way nay-sayers have demanded. There will never be a randomized clinical trial in every cancer type and for every drug, so, at some point you have to ask yourself, given all of th...

                      November 16 at 3:17 AM view post
                      Loading...
                      Load more activity
                      Loading more activity

                      About Gdpawel

                      Caregiver, Researcher
                      Ovarian Cancer
                      Cancer Treatments, Chemotherapy, Clinical Trials and Research, Conventional Treatments, Genetics, Radiation, Side Effects, Supplements, Surgery

                      I've been involved with internet cancer research for 17 years, since the days of the CompuServe Cancer Forum which involved many professionals including medical oncologists who were fascinated with this new tool for sharing ideas. I made many contacts with leading oncologists from around the country and learned a great deal regarding new developments in the treatment of cancer.

                      You are most welcome to peruse the non-afilliated, PhD-oriented cancer information website I've been the moderator for 7 years. My 12 years studying cell function analysis, which holds no boundaries across the various cancer types, makes it a perfect place for me to continue my already years of internet cancer research.

                      http://cancerfocus.org/forum/index.php?

                      We care about your feedback. Let us know how we can improve your CancerCompass experience.